MCRI and Incepta Pharmaceuticals partner to protect children from rotavirus | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 10, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 10, 2025
MCRI and Incepta Pharmaceuticals partner to protect children from rotavirus

Corporates

Press Release
03 June, 2024, 03:10 pm
Last modified: 03 June, 2024, 03:14 pm

Related News

  • Incepta Pharmaceutical, Channel i jointly hold 'World Vitiligo Day'
  • Incepta brings country's first pneumonia vaccine for all age groups 
  • Incepta hosts Annual Sales Conference 2024
  • World Alzheimer's Day observed by National Institute of Neurosciences and Incepta Pharmaceuticals
  • Bangladesh Business Summit ended 13 March

MCRI and Incepta Pharmaceuticals partner to protect children from rotavirus

Press Release
03 June, 2024, 03:10 pm
Last modified: 03 June, 2024, 03:14 pm
Representational image. Photo: Courtesy
Representational image. Photo: Courtesy

Murdoch Children's Research Institute (MCRI) and Incepta Pharmaceuticals, based in Bangladesh, have embarked on a collaboration aimed at bringing life-saving innovation to the global healthcare landscape.

MCRI has announced the signing of a non-exclusive licensing agreement with Incepta Pharmaceuticals, marking another milestone in its journey to reduce the impact of rotavirus, the most common cause of severe diarrhoea in infants and young children worldwide.

RV3-BB, adapted and developed from a naturally occurring human strain of rotavirus discovered in Melbourne by Professor Ruth Bishop AC and colleagues inthe early 1980's, offers early protection against dehydrating diarrhoea from birth. The RV3-BB vaccine, intended for neonatal or infant dosing schedules as part of routine Expanded Program on Immunization (EPI) vaccinations, has the potential to save hundreds of thousands of children's lives annually.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

In Bangladesh alone, where more than two million babies are born every year, the impact of RV3-BB could be profound. Globally, rotavirus claims the lives of about 450,000 children under the age of five annually, making the need for accessible and effective vaccines urgent.

MCRI Professor Andrew Steer, Director of Infection, Immunity and Global Health said, "This collaboration represents a significant step forward in our mission to protect vulnerable children from the effects of rotavirus infection. By joining forces with Incepta Pharmaceuticals, we are poised to make RV3-BB readily available to communities in need worldwide.

"MCRI's relentless pursuit of accessible and scalable vaccine solutions underscores our commitment to global health equity."

Abdul Muktadir, Chairman & Managing Director of Incepta Pharmaceuticals said, "We are proud to partner with MCRI in this groundbreaking endeavour. Together, we are committed to leveraging our expertise and resources to ensure that  rotavirus vaccine (RV3-BB) reaches the millions of childrenwho need it most, safeguarding the health of future generations."

With Incepta Pharmaceuticals' established reputation as a leading pharmaceutical company in Bangladesh, equipped with the capacity to produce vaccines at scale, RV3-BB vaccine is poised to make a transformative impact on childhood health worldwide.

Incepta

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational image. Photo: Syed Zakir Hossain/TBS
    Explainer: Why SSC pass rate hit a 17-year low
  • Council of Advisers' meeting on Thursday (10 July). Photo: CA Press Wing
    Govt cancels 'Sir' address directive from Hasina's rule
  • Sri Lanka cruise to seven-wicket win over Bangladesh in first T20I
    Sri Lanka cruise to seven-wicket win over Bangladesh in first T20I

MOST VIEWED

  • Graphics: TBS
    BB raises startup fund limit, drops upper age barrier
  • Workers pack undergarments at the packing section of a garment factory in Ashulia, on the outskirts of Dhaka, Bangladesh, April 19, 2025. Photo: REUTERS/Fatima Tuj Johora
    After US tariffs, jobs hang by a thread in Bangladesh's garments sector
  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • File photo of containers at Chattogram port/TBS
    US buyers push Bangladeshi exporters to share extra tariff costs
  • Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
    Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
  • Students sit for SSC exam at Motijheel Girls' High School on 10 April 2025. Photo: Mehedi Hasan/TBS
    SSC exam results out: Here's how you can check online and via SMS

Related News

  • Incepta Pharmaceutical, Channel i jointly hold 'World Vitiligo Day'
  • Incepta brings country's first pneumonia vaccine for all age groups 
  • Incepta hosts Annual Sales Conference 2024
  • World Alzheimer's Day observed by National Institute of Neurosciences and Incepta Pharmaceuticals
  • Bangladesh Business Summit ended 13 March

Features

Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

2h | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

5h | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

5h | Panorama
Women are forced to fish in saline waters every day, risking their health to provide for their families. Photo: TBS

How Mongla’s women are bearing the brunt of rising salinity

1d | Panorama

More Videos from TBS

'Hypocrisy' will not continue, Iran tells IAEA

'Hypocrisy' will not continue, Iran tells IAEA

1h | TBS World
OpenAI to release web browser in challenge to Google Chrome

OpenAI to release web browser in challenge to Google Chrome

1h | TBS World
Will the title 'Honorable and Excellency' be abolished?

Will the title 'Honorable and Excellency' be abolished?

2h | TBS Today
July Declaration must be constitutionally recognized: Akhtar Hossain

July Declaration must be constitutionally recognized: Akhtar Hossain

1h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net